Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | EVP & CFO | September 17, 2019 | September 19, 2019 |
| VivoSim Labs, INC.ONVO · Entity 8386 | President and CFO | September 15, 2020 | September 17, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 17, 2019 · Filed September 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.83 · Expires 2029-09-16 | Direct | 50,000 |
Reported balance
After 2019-09-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-09-17 · Grant · Acquired 50,000 · Balance 50,000 F1: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019.
VivoSim Labs, INC.
Report date September 15, 2020 · Filed September 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.64 · Expires 2030-09-15 | Direct | 20,000 |
Reported balance
After 2020-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-09-15 · Grant · Acquired 20,000 · Balance 20,000 F1: 25% of the option shares vest and become exercisable on September 15, 2021 and the remaining shares vest in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the option shares vest and become exercisable on September 15, 2021 and the remaining shares vest in 12 equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2020 Filed Sep 17, 2020 23:19 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0001209191-20-051047 · doc4.xml · derivative · entry 1 Heberlig Chris · CIK 0001532217 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-09-15 F1 · derivative.exercise_date: 25% of the option shares vest and become exercisable on September 15, 2021 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 20:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 50,000 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001179110-19-010487 · edgar.xml · derivative · entry 1 Heberlig Chris · CIK 0001532217 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Shares · 50,000 shares Expires 2029-09-16 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 23:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 46,000 | $0.00 Strike: $17.92 | $0.00 |
DisclosureSEC source: 0001104659-19-013177 · a4.xml · derivative · entry 1 Heberlig Chris · CIK 0001532217 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Class A Common Shares · 46,000 shares Expires 2029-03-03 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019. Read SEC document |
| September 20, 2018 Filed Sep 24, 2018 12:58 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 45,000 | $0.00 Strike: $30.93 | $0.00 |
DisclosureSEC source: 0001104659-18-058108 · a4.xml · derivative · entry 1 Heberlig Chris · CIK 0001532217 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Shares · 45,000 shares Expires 2028-09-19 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is September 20, 2018. Read SEC document |
| May 29, 2018 Filed May 29, 2018 23:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | ConversionClass B Common Shares · Derivative | 74,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-036483 · a4.xml · derivative · entry 6 Heberlig Chris · CIK 0001532217 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,920 Underlying: Class A Common Shares · 74,935 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Class B Common Shares is convertible at any time at the election of the holder into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party. F4 · derivative.exercise_date: Each share of Class B Common Shares is convertible at any time at the election of the holder into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party. F4 · derivative.expiration_date: Each share of Class B Common Shares is convertible at any time at the election of the holder into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party. Read SEC document |
| May 29, 2018 Filed May 29, 2018 23:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | ConversionSeries C Preferred Shares · Derivative | 6,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-036483 · a4.xml · derivative · entry 5 Heberlig Chris · CIK 0001532217 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 6,392 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. Read SEC document |
| May 29, 2018 Filed May 29, 2018 23:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | ConversionSeries A Preferred Shares · Derivative | 74,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-036483 · a4.xml · derivative · entry 4 Heberlig Chris · CIK 0001532217 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Shares · 74,935 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis. F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis. F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis. Read SEC document |
| May 29, 2018 Filed May 29, 2018 23:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | ConversionClass A Common Shares | 6,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-036483 · a4.xml · nonDerivative · entry 1 Heberlig Chris · CIK 0001532217 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2018 Filed May 29, 2018 23:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | PurchaseSeries C Preferred Shares · Derivative | 6,392 | $15.64 | $99,995.17 |
DisclosureSEC source: 0001104659-18-036483 · a4.xml · derivative · entry 3 Heberlig Chris · CIK 0001532217 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,392 Underlying: Class A Common Shares · 6,392 shares Expires not disclosed F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F2 · shares: Reflects the 1-for-2.73235 share consolidation effected May 11, 2018. F2 · price: Reflects the 1-for-2.73235 share consolidation effected May 11, 2018. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F2 · derivative.underlying_shares: Reflects the 1-for-2.73235 share consolidation effected May 11, 2018. F2 · balance_after: Reflects the 1-for-2.73235 share consolidation effected May 11, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.